hMG

Status

FDA-approved. FDA-approved labeling exists for menotropins for development of multiple follicles and ovulation induction in ovulatory women participating in assisted reproductive technology programmes. Labels warn about ovarian hyperstimulation syndrome, multiple births and pulmonary and vascular complications.

What it is

A menotropin preparation providing FSH and LH activity in fertility care.

What published research measured

Human menopausal gonadotropin, purified from the urine of postmenopausal women, containing both follicle stimulating hormone and luteinising hormone activity — the LH component is what distinguishes it from recombinant FSH and is the basis for its continued use in patients thought to benefit from combined activity. It has a long randomized record in assisted reproduction, and meta-analyses comparing it with recombinant FSH have generally found broadly comparable live birth rates with some differences in oocyte yield and stimulation characteristics. The risk profile is that of gonadotropin stimulation generally: ovarian hyperstimulation syndrome and multiple pregnancy, both requiring monitored cycles.

Source

FDA labeling for menotropins

Sources

• Half-life source for hMG